James K. Kihara's Insider Trades & SAST Disclosures
James K. Kihara's most recent trade in Acadia Pharmaceuticals Inc was a trade of 840 Common Stock done . Disclosure was reported to the exchange on Feb. 23, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern James K. Kihara.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 840 | 20,703 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 840 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 19.96 per share. | 23 Feb 2025 | 475 | 20,228 (0%) | 0% | 20.0 | 9,481 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 16.81 per share. | 17 Nov 2024 | 4,073 | 19,863 (0%) | 0% | 16.8 | 68,467 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 3,965 | 19,971 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 3,965 | 3,966 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 3,965 | 3,966 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 3,965 | 23,936 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 2,596 | 7,788 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 2,596 | 15,696 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 16.94 per share. | 01 May 2024 | 1,326 | 14,370 (0%) | 0% | 16.9 | 22,462 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 2,010 | 13,401 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 2,010 | 4,020 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 1,489 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 1,489 | 14,890 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 17.87 per share. | 05 Apr 2024 | 1,028 | 13,862 (0%) | 0% | 17.9 | 18,370 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 17.87 per share. | 05 Apr 2024 | 762 | 13,100 (0%) | 0% | 17.9 | 13,617 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 13,964 | 13,964 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 8,568 | 8,568 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | K. Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 840 | 11,865 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Kihara K. James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 840 | 840 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Kihara K. James | PRINCIPAL ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 24.67 per share. | 23 Feb 2024 | 474 | 11,391 (0%) | 0% | 24.7 | 11,694 | Common Stock |
| Acadia Pharmaceuticals Inc | K. Kihara James | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.30 per share. | 15 Dec 2023 | 2,000 | 11,025 (0%) | 0% | 28.3 | 56,600 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 24.15 per share. | 15 Jun 2023 | 2,000 | 9,144 (0%) | 0% | 24.2 | 48,300 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 5,947 | 17,091 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 5,947 | 9,913 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 5,947 | 9,913 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 17 May 2023 | 5,947 | 11,144 (0%) | 0% | 22.5 | 133,808 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 5,947 | 11,144 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 17,131 | 17,131 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 10,384 | 10,384 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2023 | 1,489 | 5,720 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2023 | 1,489 | 1,489 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 18.14 per share. | 07 Apr 2023 | 523 | 5,197 (0%) | 0% | 18.1 | 9,487 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2023 | 2,009 | 6,030 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2023 | 2,009 | 4,932 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 18.16 per share. | 05 Apr 2023 | 701 | 4,231 (0%) | 0% | 18.2 | 12,730 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 840 | 1,680 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 840 | 3,273 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 18.78 per share. | 23 Feb 2023 | 350 | 2,923 (0%) | 0% | 18.8 | 6,573 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2022 | 2,977 | 2,978 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2022 | 2,977 | 3,458 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 27.05 per share. | 07 Apr 2022 | 1,025 | 2,433 (0%) | 0% | 27.0 | 27,726 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 13,793 | 13,793 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 8,039 | 8,039 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 840 | 2,520 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 840 | 840 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 23.80 per share. | 23 Feb 2022 | 359 | 481 (0%) | 0% | 23.8 | 8,544 | Common Stock |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 6,187 | 6,187 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | James K. Kihara | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 3,360 | 3,360 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges